Novartis has agreed to buy Avidity Biosciences in a $12 billion biotech deal, the biggest acquisition for the Swiss drug maker in more than a decade. Joining us now is Bloomberg Intelligence is senior pharmaceutical analyst Sam Zell. Sam, thanks for joining us on the show.What does this deal tell us about potential M&A activity across the pharma space. Well, good morning to you. So this is by my count, we keep a tally of this.Of course, Bloomberg. This will be the 21st deal for 2025, where large pharma comp ...